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Background: A Phase 2a, open-label study (NCT01724086) was conducted to assess the efficacy and safety of a
once-daily, 2-direct-acting-antiviral-agent (2-DAA) combination of simeprevir + TMC647055/ritonavir ± ribavirin and
of the 3-DAA combination of simeprevir + TMC647055/ritonavir + JNJ-56914845 in chronic hepatitis C virus
genotype (GT)1-infected treatment-naïve and prior-relapse patients.
Methods: The study comprised four 12-week treatment panels: Panel 1 (n= 10; GT1a) and Panel 2-Arm 1 (n= 12; GT1b):
simeprevir 75 mg once daily + TMC647055 450 mg once daily/ritonavir 30 mg once daily + ribavirin 1000–1200 mg/day;
Panel 2-Arm 2 (n = 9; GT1b): simeprevir 75 mg + TMC647055 450 mg/ritonavir 30 mg without ribavirin; Panel 3: simeprevir
75 mg + TMC647055 600 mg/ritonavir 50 mg with (Arm 1: GT1a; n = 7) or without (Arm 2: GT1b; n = 8) ribavirin; Panel 4:
simeprevir 75 mg + TMC647055 450 mg/ritonavir 30 mg + JNJ-56914845 30 mg once daily (Arm 1: n = 22; GT1a/GT1b) or
60 mg once daily (Arm 2: n = 22; GT1a/GT1b). Primary endpoint was sustained virologic response 12 weeks after end of
treatment (12 weeks of combination treatment; SVR12).
Results: In Panel 1 and Panel 2-Arm 1, 5/10 and 6/12 (50%) GT1a/GT1b + ribavirin patients achieved SVR12, versus 3/9
(33%) GT1b without ribavirin patients in Panel 2-Arm 2. In Panel 3-Arm 1 and Panel 3-Arm 2, 6/7 (86%) GT1a + ribavirin
and 4/8 (50%) GT1b without ribavirin patients, respectively, achieved SVR12. In Panel 4, 10/14 (71%) and 14/15 (93%) GT1a
patients in Arms 1 and 2 achieved SVR12 compared with 8/8 and 7/7 (100%) GT1b patients in each arm, respectively. No
deaths, serious adverse events (AEs), Grade 4 AEs or AEs leading to treatment discontinuation occurred.
Conclusions: The 2- and 3-DAA combinations were well tolerated. High SVR rates of 93% and 100% in GT1a- and GT1b-
infected patients, respectively, were achieved in this study by combining simeprevir with JNJ-56914845 60 mg and
TMC647055/ritonavir.
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Interferon (IFN)-free regimens comprising direct-acting
antivirals (DAA) with different mechanisms of action
can result in high sustained virologic response (SVR)
rates in patients chronically infected with hepatitis C
virus (HCV). Combination regimens comprising an
HCV NS3/4A protease inhibitor (PI), a non-nucleoside
inhibitor (NNI) of the HCV NS5B polymerase and/or an
HCV NS5A replication complex inhibitor with/without
ribavirin have been shown to be successful in the treat-
ment of chronic HCV infection [1]. For example, the
combination of the PI paritaprevir, the NNI dasabuvir
and the NS5A inhibitor ombitasvir, with ritonavir in-
cluded as a pharmacologic booster for paritaprevir, is ap-
proved for the treatment of chronic HCV genotype (GT)
1 infection. In the PEARL-III (HCV GT1b) and PEARL-
IV (HCV GT1a) Phase 3 studies, treatment of previously
untreated patients with paritaprevir/ritonavir, dasabuvir
and ombitasvir for 12 weeks resulted in SVR 12 weeks
after end of treatment (SVR12) rates of 99.5% and 97.0%
in the presence of ribavirin, and 99.0% and 90.2% in the
absence of ribavirin, respectively [2].
Simeprevir is a once-daily, HCV NS3/4A PI approved
as part of an IFN-free combination with sofosbuvir for
HCV GT1 infection. In addition, simeprevir with
sofosbuvir is approved for HCV GT4 infection and
HCV/human immunodeficiency virus (HIV) co-infection
in the European Union (EU). Simeprevir is also approved
in combination with pegylated IFN (pegIFN)/ribavirin
for chronic HCV GT1 and GT4 infection in the United
States and EU [3]. Simeprevir is a cytochrome P450
(CYP) 3A substrate and mild inhibitor (intestinal only).
Simeprevir also inhibits organic anion transporting
polypeptide (OATP) 1B1/3 and P-glycoprotein [4].
TMC647055 is an NNI of the HCV NS5B polymerase,
binding in the NNI-1 pocket on the polymerase.
TMC647055 has in vitro antiviral activity against HCV
GT1, 3, 4, 5 and 6 [5]. In a Phase 1 study
(NCT01202825), TMC647055 1000 mg twice daily in
combination with simeprevir 150 mg once daily for
10 days demonstrated good antiviral activity and was
well tolerated in HCV GT1a- and GT1b-infected pa-
tients [6]. However, the systemic exposure to both com-
pounds decreased during treatment to levels potentially
lower than required for complete viral suppression. Co-
administering TMC647055 with the potent CYP3A4 in-
hibitor ritonavir was expected to increase exposure by
overcoming CYP3A4 induction [5].
JNJ-56914845 (previously known as GSK-2336805) is a
potent HCV NS5A replication complex inhibitor, with
in vitro antiviral activity against HCV GT1, 4, 5 and
6a/6b [7, 8]. It is a CYP3A and P-glycoprotein substrate
and, in vitro, it inhibits P-glycoprotein, OATP1B1/3 and
breast cancer resistance protein (data on file).This Phase 2a, open-label study (NCT01724086)
assessed the efficacy, pharmacokinetics, safety and toler-
ability of the 2-DAA combination of simeprevir with
TMC647055 and a low dose of ritonavir with or without
ribavirin for 12 weeks in chronic HCV GT1-infected
treatment-naïve and prior-relapse patients. The study also
included the addition of a third DAA, JNJ-56914845, to
the simeprevir and TMC647055 combination to assess the
potential of further increasing the efficacy of the regimen
by combining three DAAs with different mechanisms of
action. Results from the final analysis, when all patients in
all panels had completed the study, are presented here.
Methods
Patients and study design
This was a Phase 2a, open-label study, conducted be-
tween 12 September 2012 and 16 December 2014 at 12
sites in Belgium and Germany. The study was approved
by the Institutional Review Board or Independent Ethics
Committee at each participating centre, and met the eth-
ical principles of the Declaration of Helsinki and Good
Clinical Practice guidelines. All patients provided writ-
ten, informed consent.
Adults (18–70 years of age) with chronic HCV GT1a/
GT1b infection and screening plasma HCV RNA
>10,000 IU/mL who were treatment-naïve or had re-
lapsed following previous treatment with pegIFN/ribavi-
rin were eligible for inclusion. Patients had to have a
documented liver biopsy within 3 years of the screening
visit, or have an elastography prior to first dosing.
Exclusion criteria included liver cirrhosis, hepatic de-
compensation, liver disease of non-HCV aetiology, infec-
tion/co-infection with non-GT1a/GT1b HCV, hepatitis
A or B, or HIV-1/-2, and significant laboratory abnor-
malities, including total bilirubin ≥1.5 x upper limit of
normal and platelet count <90,000/mm3. Patients who
had received prior HCV-specific DAA treatment or a
liver transplant were also excluded.
The study comprised four 12-week treatment panels
(Fig. 1). Panels 1 and 2, which ran in parallel, comprised
the first part of the study and were sequentially followed
by Panels 3 and 4. Panels 1–3 evaluated simeprevir in
combination with TMC647055/ritonavir (at two different
doses of TMC647055) with ribavirin in GT1a-infected
patients and with or without ribavirin in GT1b-infected
patients. Panel 4 evaluated the triple combination of sime-
previr with TMC647055/ritonavir plus the NS5A inhibitor
JNJ-56914845 at a low and high dose in GT1a/b-infected
patients.
More specifically, patients in Panels 1 and 2 received
simeprevir 75 mg once daily, TMC647055 450 mg once
daily, ritonavir 30 mg once daily and ribavirin 1000–
1200 mg (patients in Panel 2-Arm 2 did not receive riba-
virin). Patients in Panel 3 received simeprevir 75 mg
Week
Panel 1 GT1a
Panel 2
SVR12
0 12 24
SMV 75 mg +
TMC647055/RTV 450/30 mg + RBVa
Arm 1
GT1b
SMV 75 mg +
TMC647055/RTV 450/30 mg + RBV
a
Optional follow-up with pegIFN + RBV
from Week 13 to Weeks 24 or 48
Arm 2
GT1b
SMV 75 mg +
TMC647055/RTV 450/30 mg
Panel 3
Arm 1
GT1a
SMV 75 mg +
TMC647055/RTV 600/50 mg + RBVa
Arm 2
GT1b
SMV 75 mg + 
TMC647055/RTV 600/50 mg
Panel 4
Arm 1
GT1a/1b
SMV 75 mg +
TMC647055/RTV 450/30 mg + 
JNJ-56914845 30 mg
Arm 2
GT1a/1b
SMV 75 mg + 
TMC647055/RTV 450/30 mg +  
JNJ-56914845 60 mg 
Fig. 1 Study design. aRibavirin given twice daily at a dose of 1000–1200 mg. Follow-up therapy with pegIFN/RBV was based on on-treatment response
and was initiated only if: Week 4 HCV RNA ≥25 IU/mL (Panels 1–3: 36 weeks of follow-up therapy); Week 4 HCV RNA <25 IU/mL detectable or HCV
RNA confirmed detectable between Week 4 and Week 11 (Panels 1–2: 12 weeks of follow-up therapy). GT genotype, HCV hepatitis C virus,
pegIFN pegylated interferon α-2a, RBV ribavirin, RTV ritonavir, SMV simeprevir, SVR12 sustained virologic response 12 weeks after end of treatment
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daily, ritonavir 50 mg once daily and ribavirin 1000–
1200 mg (patients in Panel 3-Arm 2 did not receive riba-
virin). Patients in Panel 4 received simeprevir 75 mg
once daily, TMC647055 450 mg once daily, ritonavir
30 mg once daily and JNJ-56914845 30 (Arm 1) or
60 mg (Arm 2) once daily. Simeprevir was dosed at
75 mg once daily (rather than the 150 mg dose ap-
proved) to account for CYP3A inhibition by ritonavir,
which is not a part of the approved regimen for simepre-
vir. Further details on the dosing rationale are provided
in Additional file 1. For ethical reasons, patients in
Panels 1–3 received follow-up treatment with pegIFN/ri-
bavirin for an additional 12 or 36 weeks if their Week-4
HCV RNA levels did not comply with predefined criteria
(Fig. 1). For patients in Panel 4 receiving the 3-DAA
regimen, no follow-up treatment was planned.
Central randomisation was implemented in Panel 2,
with patients randomly assigned 1:1 to Arm 1 or Arm 2
based on a computer-generated schedule prepared be-
fore the study, balanced by using randomly permuted
blocks, and stratified by IL28B genotype (CC and non-
CC). Patients in Panel 3 were not randomised as their
treatment was dependent on their HCV geno/subtype
(1a or 1b) (Fig. 1). In Panel 4, patients were randomised
in a 1:1 ratio between Arm 1 or Arm 2, stratified by
HCV geno/subtype.To avoid unnecessary drug exposure, the following vi-
rologic stopping rules were adopted: all study drugs were
discontinued for patients with viral breakthrough (con-
firmed on-treatment increase of >1 log10 IU/mL in HCV
RNA from the lowest level reached, or confirmed HCV
RNA >100 IU/mL in patients whose HCV RNA had pre-
viously been <25 IU/mL), or with inadequate virologic
response (confirmed HCV RNA >100 IU/mL at Week 4
or afterwards until Week 11).
Details on protocol deviations are provided in
Additional file 1.
Outcomes
The primary efficacy endpoint was SVR12. Patients
achieved SVR12 if they received no pegIFN/ribavirin
follow-up treatment after 12 weeks of combination treat-
ment (Panels 1–3 only) and achieved HCV RNA
<25 IU/mL undetectable/detectable 12 weeks after actual
end of treatment (Panels 1–4). Patients in Panels 1–3
who received follow-up therapy and had HCV RNA
<25 IU/mL at 12 weeks after end of treatment were also
classed as having achieved SVR12; however, they were
considered as failures with regards to the primary end-
point of the study, which focused on the 12-week DAA
therapy. The primary safety endpoints included the pro-
portion of patients with adverse events (AEs), serious
AEs (SAEs) or abnormal changes in safety-related
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proportion of patients with SVR 24 weeks after end of
treatment (SVR24); Week-4 pharmacokinetics of the
study drugs; on-treatment virologic failure, including pa-
tients with viral breakthrough (defined in the previous
section); viral relapse (defined as HCV RNA <25 IU/mL
undetectable at the actual end of treatment and con-
firmed HCV RNA ≥25 IU/mL during post-treatment
follow-up); and the presence of HCV NS3/4A, NS5A
and/or NS5B variants at baseline and at time of failure
in patients not achieving SVR.Assessments
Blood samples for HCV RNA level determination were
collected at screening and at predefined time points
throughout the treatment phase and follow-up period.
HCV RNA was measured using the COBAS® TaqMan®
HCV Test version 2.0 (Roche Molecular Diagnostics,
Pleasanton, CA, USA) for use with the High Pure Sys-
tem assay (lower limit of quantification: 25 IU/mL; limit
of detection: 10–15 IU/mL).
HCV geno/subtypes were determined pre-treatment
based on sequencing of a part of the NS5B gene (at base-
line) when available or by the VERSANT® HCV Genotype
2.0 assay (LiPA) or Trugene HCV Genotyping assay (at
screening) (Siemens Healthcare Diagnostics, Erlangen,
Germany).
Standard population-based sequencing of the HCV
NS3/4A and NS5B regions in Panels 1–3 and of the
NS3/4A, NS5A and NS5B regions in Panel 4 was per-
formed at baseline for all patients and post-baseline for
patients not achieving SVR12 based on the HCV RNA
changes observed in each individual patient and the
limits of the sequencing assay.
Plasma pharmacokinetic samples for simeprevir,
TMC647055, ritonavir and JNJ-56914845 were col-
lected over 24 h (pre-dose, 1, 2, 3, 4, 5, 6, 8, 10, 12
and 24 h post-dose) at Week 4 from all patients and
assayed using validated liquid chromatography-tandem
mass spectrometry methods with lower limits of
quantification for simeprevir, TMC647055, ritonavir
and JNJ-56914845 of 5.0, 5.0, 2.0 and 1.0 ng/mL, re-
spectively (data on file) [9]. Pharmacokinetic parame-
ters including maximum plasma concentration (Cmax)
and area under the plasma concentration–time curve
over 24 h (AUC0–24h) were calculated using non-
compartmental analysis (Phoenix WinNonlin® 6.2.1;
Certara, Princeton, NJ, USA).
AEs were monitored throughout the treatment phase
and follow-up period and up to 24 weeks after actual
end of treatment. AEs were coded using the Medical
Dictionary for Regulatory Activities (version 16.0 for
Panels 1 and 2 and version 17.0 for Panels 3 and 4).Statistical analyses
Statistical analyses were performed using SAS® version
9.1 or higher (SAS Institute Inc, Cary, NC, USA).
No formal sample size calculations were performed as
this was a proof-of-concept study. For each efficacy end-
point, the proportion of patients was summarised de-
scriptively together with a 95% confidence interval by
treatment group and population. The change in log10
HCV RNA from baseline at all time points was calcu-
lated using descriptive statistics. Pharmacokinetic pa-
rameters were calculated using non-compartmental
analysis (Phoenix WinNonlin® 6.2.1). All safety and toler-
ability data were summarised descriptively.
All analyses were conducted using data from the
intent-to-treat population, which comprised all patients
who received at least one dose of study drug.Results
Patient disposition and baseline characteristics
In total, 125 patients were screened, and 90 (n = 10, 21, 15
and 44 in Panels 1, 2, 3 and 4, respectively) were treated
(intent-to-treat population) (Fig. 2). Four (3%) patients
discontinued the study prematurely (lost to follow-up,
n = 3 [Panels 2 and 3]; withdrawal of consent, n = 1
[Panel 4]).
In Panel 1, 5/10 (50%) patients completed their treat-
ment regimen. In Panel 2, the majority of patients com-
pleted treatment (GT1b/with ribavirin group: 11/12
[92%]; GT1b/without ribavirin group, 8/9 [89%]). Most
patients also completed treatment in Panel 3 (GT1a/with
ribavirin, 7/7 [100%]; GT1b/without ribavirin, 7/8 [88%])
and Panel 4 (30-mg group, 22/22 [100%]; 60-mg group,
21/22 [96%]). All treatment discontinuations were due
to viral breakthrough, as detailed in the next section.
Baseline demographics and disease characteristics are
shown in Table 1.Virologic response
Figure 3 shows the treatment outcome in each of the
four panels. In Panel 1, 5/10 (50%) patients achieved
SVR12. In Panel 2, SVR12 was achieved in 6/12 (50%)
and 3/9 (33%) patients in the GT1b/with ribavirin and
GT1b/without ribavirin groups, respectively. In Panel 3,
6/7 (86%) and 4/8 (50%) patients in the GT1a/with riba-
virin and GT1b/without ribavirin groups, respectively,
achieved SVR12. In Panel 4, SVR12 was achieved in
18/22 (82%) and 21/22 (95%) patients in the JNJ-56914845
30- and 60-mg groups, respectively. In the 30-mg group,
SVR12 was achieved in 10/14 (71%) GT1a/other-infected
patients and in all (8/8; 100%) GT1b-infected patients. In
the 60-mg group, SVR12 was achieved in 14/15 (93%)
GT1a/other-infected patients and in all (7/7; 100%)
GT1b-infected patients.
Not randomised
and treated
(with RBV):
N=10
Panel 1
Failures:
N=7
Screened:
N=17
DAA treatment only:
N=10
Completed: N=10
Completed: N=11 Completed: N=8
Panel 2
Failures:
N=7
DAA only:
N=8
DAA + FU
treatment:
N=4
DAA only:
N=7a
DAA + FU
treatment:
N=2
Screened:
N=28
Randomised and treated
(with RBV):
N=12
Randomised and treated
(without RBV):
N=9
Discontinued:
N=1 
(lost to FU)
Discontinued:
N=1 
(lost to FU)
Not randomised
and treated
(with RBV):
N=7
Not randomised
and treated
(without RBV):
N=8
GT1a
Screened:
N=12
Panel 3
Failures:
N=5
Completed: N=7 Completed: N=7
Failures:
N=1
GT1b
Screened:
N=9
Discontinued: N=1
(lost to FU)
Completed:
N=12
Completed:
N=15
Completed:
N=9
Completed:
N=7
30 mg
JNJ-56914845:
N=13b
60 mg
JNJ-56914845:
N=15
30 mg
JNJ-56914845:
N=9b
60 mg
JNJ-56914845:
N=7
GT1a
Screened:
N=38
Failures:
N=10
Failures:
N=4
GT1b
Screened:
N=21
Randomised and treated:
N=28
Discontinued:
N=1 
(withdrawal of 
consent)
Randomised and treated:
N=16
Randomised and not treated
N=1
Panel 4
b) Panel 2a) Panel 1
d) Panel 4c) Panel 3
Fig. 2 Patient disposition. aIn Panel 2, one patient in the GT1b/without RBV group had <25 IU/mL detectable HCV RNA at Week 4 and, therefore, met
the criterion for a 12-week follow-up treatment with pegIFN/RBV. This patient refused to receive follow-up treatment. bIn Panel 4, the results of the
Trugene or LiPA test performed at screening were used to randomise the patients to the 30-mg or 60-mg dose of JNJ-56914845. For
analyses purposes, NS5B sequencing was used to determine the HCV geno/subtype. Based on this method, the geno/subtype for two
patients in the 30-mg group was found to be non-1a, non-1b (1c, n = 1; 1l, n = 1) based on geno/subtyping using NS5B sequencing.
These two patients were analysed together with the GT1a-infected patients in the category ‘GT1a/other’. DAA direct-acting antiviral agent,
FU follow-up, GT genotype, HCV hepatitis C virus, pegIFN pegylated interferon α-2a, RBV ribavirin
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achieve SVR24, with the exception of one patient in
Panel 1 and one patient in the GT1b/without ribavirin
group in Panel 3 who had HCV RNA ≥25 IU/mL
24 weeks after end of treatment (1,830,000 IU/mL and
2770 IU/mL, respectively).
An overview of treatment outcome, including reasons
for not achieving SVR12, is shown in Fig. 3. A total of
5/10 (50%), 1/12 (8%) and 1/9 (11%) patients in Panel 1
and in the GT1b/with ribavirin and GT1b/without riba-
virin groups of Panel 2, respectively, experienced viral
breakthrough. In Panel 3, 1/8 (13%) patients in the
GT1b/without ribavirin group had viral breakthrough
compared with 1/22 (5%) patients in the 60-mg group
of Panel 4 (Fig. 3). Among the patients withundetectable HCV RNA at end of treatment and with
at least one post-treatment follow-up HCV RNA meas-
urement available, 2/6 patients (33%) in each of the
Panel 2 and Panel 3 GT1b/without ribavirin groups and
4/14 (18%) GT1a-infected patients in the Panel 4 30-
mg group experienced viral relapse. At the time of the
final analysis, one patient in Panel 1 and one patient in the
Panel 3 GT1b/without ribavirin group achieved SVR12
but had HCV RNA ≥25 IU/mL 24 weeks after end of
treatment.
Virologic resistance testing
At baseline, the NS3 Q80K polymorphism was observed
in 2/10 (20%) GT1a-infected patients in Panel 1 and in
2/13 (15%) GT1a-infected patients in the 30-mg group
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Fig. 3 Treatment outcome in (a) Panels 1–3, and (b) Panel 4. SVR12 data
shown represent SVR12 achieved after treatment with only the
combination of SMV + TMC647055/RTV ± RBV. In the Panel 2 GT1b/with
RBV and GT1b/without RBV arms, four and two patients, respectively,
had follow-up therapy with pegIFN/RBV and are, therefore, not included
in the SVR12 category that focuses on SVR12 after 12 weeks of DAA
treatment. Among them, five patients achieved SVR12 after completing
follow-up therapy; one patient refused to receive follow-up treatment
and was lost to follow-up. One additional patient in the Panel 2 GT1b/
without RBV group had <25 IU/mL detectable HCV RNA at Week 4 and,
therefore, met the criterion for the 12-week follow-up treatment
with pegIFN/RBV; however, this patient refused to receive follow-
up treatment. DAA direct-acting antiviral agent, DET detectable,
EOT end of treatment, FU follow-up, GT genotype, HCV hepatitis
C virus, pegIFN pegylated interferon α-2a, RBV ribavirin, RTV
ritonavir, SMV simeprevir, SVR12 sustained virologic response
12 weeks after end of treatment, VBT viral breakthrough
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with baseline Q80K in Panel 1, and one of the two pa-
tients in Panel 4 achieved SVR12. In 5/42 (12%) patients
with NS5A sequencing data available in Panel 4, baseline
NS5A polymorphisms were detected at positions 28, 30,
31 and/or 93. Of those, only L31M (n = 1) and Y93C
(in combination with M28V; n = 1), both detected in
GT1a-infected patients, are associated with in vitro resist-
ance to JNJ-56914845 [8]. Details on NS5B baseline poly-
morphisms are provided in Additional file 1.
Virologic failure (including the two patients who achieved
SVR12 but had HCV RNA ≥25 IU/mL 24 weeks after end
of treatment) was, in the majority of patients, associatedwith the emergence of simeprevir and TMC647055
resistance-associated variants (RAVs) in Panels 1–3 and
simeprevir and JNJ-56914845 RAVs with or without
TMC647055 RAVs in Panel 4 at time of failure. In line with
the previously characterised simeprevir resistance profile,
most GT1b-infected patients harboured an emerging muta-
tion at NS3 position 168, while emerging mutations in
GT1a-infected patients were mostly observed at NS3 pos-
ition 155 (R155K alone or in combination with a Q80R;
R155S) at time of failure. TMC647055 RAVs were only ob-
served at NS5B position 495 (mainly P495L), consistent
with the resistance profile of NNI-1 polymerase inhibitors.
In all patients with virologic failure in Panel 4, emerging
JNJ-56914845 RAVs at NS5A positions 30 and/or 31 were
detected at time of failure. Treatment-emergent RAVs in
NS3 and NS5B became undetectable in many of the pa-
tients after treatment was stopped, while emerging RAVs in
NS5A could still be detected by population sequencing at
the end of the study in the five patients who failed the
3-DAA treatment.Pharmacokinetics
Co-administration of high-dose TMC647055/ritonavir
(600/50 mg) increased simeprevir exposure compared
with low-dose TMC647055/ritonavir (450/30 mg).
Simeprevir Cmax values were increased by 2.0-fold and
AUC0–24h values by 1.9- to 2.3-fold, respectively,
following co-administration with TMC647055/ritonavir
(600/50 mg vs 450/30 mg) with ribavirin (Panel 3-Arm 1 vs
Panel 1) or without ribavirin (Panel 3-Arm 2 vs
Panel 2-Arm 2) (Additional file 2: Figure S1a).
A more than dose-proportional increase in TMC647055 ex-
posure occurred following co-administration of TMC647055/
ritonavir 600 mg/50 mg once daily (Panel 3-Arm 2) com-
pared with 450 mg/30 mg once daily (Panel 2-Arm 2) with
simeprevir (Cmax: 2.6-fold increase; AUC0–24h: 2.4-fold in-
crease) (Additional file 2: Figure S1b).
Co-administration of high-dose JNJ-56914845 60 mg
once daily with simeprevir 75 mg once daily +
TMC647055/ritonavir 450 mg/30 mg once daily increased
simeprevir exposure (1.2-fold increase in both Cmax and
AUC0–24h vs without JNJ-56914845) (Additional file 2:
Figure S1a), but had minimal effect on TMC647055 and
ritonavir exposure (Additional file 2: Figure S1b and c).
A dose-proportional increase in exposure to JNJ-
56914845 60 mg versus 30 mg once daily was ob-
served when co-administered with simeprevir 75 mg +
TMC647055/ritonavir 450 mg/30 mg once daily (Panel
4-Arm 2 vs Panel 4-Arm 1: Cmax 821 vs 389 ng/mL,
AUC0–24h 7747 vs 3358 ng · h/mL) (Additional file 2:
Figure S1d; Additional file 3: Table S1).
No differences were observed in simeprevir, TMC647055
or ritonavir pharmacokinetics based on ribavirin use
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Additional file 6: Table S4).
Safety
No patients discontinued any of the study drugs due to
an AE, and there were no SAEs or deaths.
The incidence of AEs was similar between Panels 1
and 2, and Panel 3 (Table 2). In Panels 1 and 2, all re-
ported AEs were Grade 1 or 2, and there were no clinic-
ally relevant differences among patients treated with
ribavirin and those who did not receive ribavirin in
terms of the incidence or severity of AEs. In Panel 3, all
AEs were Grade 1 or 2, with the exception of one pa-
tient (GT1b/without ribavirin group) who experienced a
Grade 3 AE (hypercholesterolaemia). This AE was not
serious and was not considered related to simeprevir,
TMC647055 or ritonavir by the investigator; the AE was
ongoing at the time of the final analysis. A higher inci-
dence of patients in Panel 3 treated with ribavirin expe-
rienced a Grade 1 or 2 AE compared with those who did
not receive ribavirin. All AEs in Panel 4 were Grade 1 or 2,
with the exception of one patient who experienced a
Grade 3 increase in white blood cell count (not related to
any study drug). There were no clinically relevant differ-
ences in the incidence of AEs between patients treated
with JNJ-56914845 at either dose (Table 2).
The most frequently (in >20% of patients) reported
AEs during the treatment phase were as follows; Panels
1 and 2: headache (14/31 [45%]), fatigue (9/31 [29%])
and influenza-like illness (7/31 [23%]); Panel 3: nausea
(7/15 [47%]), headache (7/15 [47%]), diarrhoea (5/15Table 2 Summary of adverse events during the treatment phase (in
Simeprevir 75 mg +
TMC647055/ritonavir
450/30 mg
Sim
TMC
600/
Panel 1 Panel 2 Pan
GT1a/with
ribavirin
(n = 10)
GT1b/with
ribavirin
(n = 12)
GT1b/without
ribavirin
(n = 9)
GT1
riba
(n =
Any AE, n (%) 10 (100) 12 (100) 7 (78) 6 (8
Worst Grade 1, n (%) 6 (60) 7 (58) 4 (44) 5 (7
Worst Grade 2, n (%) 4 (40) 5 (42) 3 (33) 1 (1
Worst Grade 3, n (%) 0 (0) 0 (0) 0 (0) 0 (0
Worst Grade 4, n (%) 0 (0) 0 (0) 0 (0) 0 (0
Leading to permanent stop of
study drugs, n (%)
0 (0) 0 (0) 0 (0) 0 (0
Serious AE, n (%) 0 (0) 0 (0) 0 (0) 0 (0
Death, n (%) 0 (0) 0 (0) 0 (0) 0 (0
AE adverse event, GT genotype
aGT1a/other, n = 14; GT1b, n = 8. GT1a/other includes one patient with HCV GT1c a
bGT1a/other, n = 15; GT1b, n = 7
cHypercholesterolaemia, not related to any study drug
dIncrease in white blood cell count, not related to any study drug[33%]), fatigue (4/15 [27%]) and pruritus (4/15 [27%]);
Panel 4: headache (15/44 [33%]), diarrhoea (14/44 [32%])
and fatigue (13/44 [30%]).
The majority of graded laboratory abnormalities were
Grade 1 or 2 and were not clinically significant. Grade 3
or 4 laboratory abnormalities were observed in <10% of
patients in all panels (further details are provided in
Additional file 1). Hyperbilirubinaemia was reported as a
laboratory-related AE in 1 (3%) patient in Panels 1 and 2
(considered possibly related to TMC647055 and sime-
previr) and 1 (2%) patient in the 60-mg group in Panel 4
(considered possibly related to TMC647055, ritonavir
and JNJ-56914845, and probably related to simeprevir).
Both hyperbilirubinaemia AEs were Grade 1 or 2 in
severity.
Discussion
This was a proof-of-concept study performed to explore
the efficacy and safety of the 2-DAA combination of the
HCV NS3/4A PI simeprevir and the HCV NS5B NNI
TMC647055 administered with ritonavir ± ribavirin, and
of the 3-DAA combination of simeprevir, TMC647055
and the HCV NS5A inhibitor JNJ-56914845 administered
with ritonavir in HCV GT1-infected patients. The results
suggest that the addition of JNJ-56914845 (60 mg) to the
2-DAA regimen of simeprevir and TMC647055 was
highly beneficial in improving the efficacy of the combin-
ation treatment in patients with HCV GT1 infection.
Overall, the 2-DAA combination of low-dose
TMC647055/ritonavir plus simeprevir, with or without
ribavirin, did not demonstrate high efficacy in GT1-tent-to-treat population)
eprevir 75 mg +
647055/ritonavir
50 mg
Simeprevir 75 mg +
TMC647055/ritonavir
450/30 mg +
JNJ-56914845 30 mg
Simeprevir 75 mg +
TMC647055/ritonavir
450/30 mg + JNJ-56914845
60 mg
el 3 Panel 4
a/with
virin
7)
GT1b/without
ribavirin
(n = 8)
GT1a/b/other
(n = 22)a
GT1a/b/other
(n = 22)b
6) 6 (75) 20 (91) 22 (100)
1) 3 (38) 15 (68) 15 (68)
4) 2 (25) 5 (23) 6 (27)
) 1 (13)c 0 (0) 1 (5)d
) 0 (0) 0 (0) 0 (0)
) 0 (0) 0 (0) 0 (0)
) 0 (0) 0 (0) 0 (0)
) 0 (0) 0 (0) 0 (0)
nd one patient with GT1l, as determined by NS5B sequencing
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HCV GT1a-infected patients treated with the 2-DAA
combination and ribavirin was 86% (6/7) for the high
dose of TMC647055/ritonavir, and 50% (5/10) for the
low dose of TMC647055/ritonavir, indicating a dose-
dependent increase in efficacy of TMC647055/ritonavir.
The increased dose was not associated with an increase
in AEs and there were no safety concerns regarding the
use of ritonavir. Although the 2-DAA combination and
the high dose of TMC647055/ritonavir demonstrated a
higher SVR12 rate in GT1a-infected patients compared
with the low dose of TMC647055/ritonavir, this was not
observed in GT1b-infected patients who received the
2-DAA combination without ribavirin (SVR12 for the
low- vs high-dose TMC647055/ritonavir: 33% [3/9] vs
50% [4/8], respectively). Although data are limited,
these suggest the addition of ribavirin may be re-
quired to increase SVR12 in a 2-DAA regimen com-
bining an NS3/4A PI and an NS5B NNI.
In Panel 1, neither of the two GT1a-infected patients
with an NS3 Q80K polymorphism at baseline achieved
SVR12. Moreover, viral breakthrough was frequently ob-
served with the 2-DAA combination (ranging from 8–50%)
compared with a frequency of 5% with the 3-DAA combin-
ation (1/22 patient who received the 3-DAA combination
with JNJ-56914845 [60 mg]).
The 3-DAA combination resulted in an overall SVR12
rate of 95% with 60 mg JNJ-56914845. All GT1b-
infected patients (7/7; 100%) treated with the 3-DAA
combination achieved SVR12, and the majority of GT1a-
infected patients (14/15; 93%) also achieved SVR12 fol-
lowing treatment with this regimen. The SVR12 rates
observed with this combination therapy are consistent
with those reported in Phase 3 studies that assessed the
combination of the PI paritaprevir with the NNI dasabu-
vir and the NS5A inhibitor ombitasvir in treatment-
naïve or treatment-experienced, non-cirrhotic, HCV
GT1-infected patients [2, 10–12].
The simeprevir resistance profile observed in all panels
in this study was similar to that observed in the simepre-
vir Phase 3 studies in the presence of pegIFN/ribavirin
[13–15]. A genotypic and phenotypic analysis of baseline
HCV isolates from all patients who participated in this
study, as well as of isolates obtained at the time of failure
and at the end of study from patients with virologic
failure, are described in full in a separate paper (Leen
Vijgen, Kim Thys, An Vandebosch, Pieter Van Remoortere,
René Verloes, Sandra De Meyer. Virology analysis in HCV
genotype 1-infected patients treated with the combination
of simeprevir and TMC647055/ritonavir, with and without
ribavirin, and JNJ-56914845, in preparation).
The interaction between the drugs assessed in this
study had previously been evaluated in healthy volunteers
[16]. In that study, co-administration of simeprevirincreased exposure (AUC0–24h) of JNJ-56914845 2.6-fold
with no additional effect when TMC647055/ritonavir was
added. Co-administration with JNJ-56914845 resulted in
small increases in the plasma concentrations of simeprevir
and TMC647055. These increases were not considered to
be clinically relevant for either DAA [16]. In the current
study, administration of simeprevir 75 mg once daily in
combination with TMC647055/ritonavir in HCV-infected
patients resulted in simeprevir exposures within the range
observed in historical data for simeprevir when dosed at
150 mg once daily (data on file). In addition, high ex-
posure to TMC647055 was achieved when administered
in combination with ritonavir.
Both the 2-DAA and the 3-DAA regimens were well tol-
erated. There were no deaths, SAEs, Grade 4 AEs or AEs
leading to temporary/permanent treatment discontinu-
ation in any of the four panels. In addition, there were no
Grade 3 or 4 laboratory-related AEs that were considered
related to any of the study drugs. Differences in AE inci-
dence among patients who received ribavirin and those
who did not in Panels 1 and 2 (Table 2) were a result of
ribavirin-related adverse drug reactions, as were the re-
spective differences observed in the incidence of labora-
tory abnormalities in Panels 1–3 (see Additional file 1). A
comparable safety profile was observed with TMC647055/
ritonavir 450/30 mg and TMC647055/ritonavir 600/50 mg
(Panels 1–3) and also between the JNJ-56914845 30-mg
and 60-mg doses (Panel 4).Conclusion
High SVR rates of 93% and 100% in GT1a- and GT1b-
infected patients, respectively, were achieved in this
study by combining simeprevir 75 mg with JNJ-
56914845 60 mg and TMC647055/ritonavir 450/30 mg.
Lower SVR rates were observed without the inclusion of
JNJ-56914845. Based on the results of this study, the
efficacy and safety of DAA-combination regimens target-
ing the same viral proteins as the drugs in this study
(i.e., the HCV NS5B polymerase, the HCV NS5A protein
and the HCV NS4/4A protease) are being investigated
further.Additional files
Additional file 1: Further information on the methods of the study,
including dosing rationale and protocol deviations are included. In
addition, further virologic resistance testing and safety results are
included. (DOCX 16 kb)
Additional file 2: Figure S1. Mean (SD) plasma concentration versus
time profile for: (a) simeprevir; (b) TMC647055; and (c) ritonavir in Panels
1–4; and for (d) JNJ-56914845 in Panel 4. RBV ribavirin, RTV ritonavir, SD
standard deviation, SMV simeprevir. (DOCX 564 kb)
Additional file 3: Table S1. Week-4 JNJ-56914845 pharmacokinetic
parameters after administration in Panel 4. (DOCX 14 kb)
Bourgeois et al. BMC Gastroenterology  (2017) 17:26 Page 10 of 11Additional file 4: Table S2. Week-4 simeprevir pharmacokinetic param-
eters after administration in (a) Panels 1–3 and (b) Panel 4. (DOCX 15 kb)
Additional file 5: Table S3. Week-4 TMC647055 pharmacokinetic param-
eters after administration in (a) Panels 1–3 and (b) Panel 4. (DOCX 15 kb)
Additional file 6: Table S4. Week-4 ritonavir pharmacokinetic parame-
ters after administration in (a) Panels 1–3 and (b) Panel 4. (DOCX 15 kb)
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